Access to IP SENISCA holds patent-protected innovations in reversing cellular senescence with oligonucleotide-based therapeutics, suggesting opportunities for partnerships or licensing discussions around platform technologies and potential co-development deals.

Funding Momentum With recent funding rounds totaling around GBP 3.7 million and UK Innovate UK grants, there is demonstrated investor confidence and a favorable timeline for clinical and preclinical collaboration, indicating readiness for partner-led funding or grant-supported programs.

Leadership Hire New CEO appointed in late 2023 and a recent Chair of the Board appointment signal strategic refocusing, making SENISCA a timely target for strategic alliances, advisory roles, or executive-level partnerships to drive market entry.

Therapeutic Focus Active development of RNA-based therapeutics targeting aging and idiopathic pulmonary fibrosis positions SENISCA for collaborations with pharma focused on age-related diseases, respiratory conditions, and precision oligonucleotide platforms.

Strategic Partnerships Past investments from LifeSpan Vision Ventures and recognition through Nature Spinoff Prize indicate a track record of validating the science; this improves credibility for outreach to potential co-development, licensing, or co-funding collaborations with biotech firms.